• Kevin N Foster, R Fred Mullins, David G Greenhalgh, Richard L Gamelli, Paul Glat, Christopher W Lentz, Steven A Kahn, Claus Brandigi, Paul Fredlund, and W Allan Alexander.
• Arizona Burn Center at Maricopa Medical Center, Phoenix, AZ, USA.
• J. Pediatr. Surg. 2011 Oct 1;46(10):1992-9.

BackgroundPrevious studies of recombinant human thrombin (rThrombin) enrolled adult and adolescent patients. This phase 4, open-label, single-group study was conducted in pediatric patients undergoing synchronous burn wound excision and skin grafting to provide information regarding the safety and immunogenicity of rThrombin (primary and secondary endpoints) in this population.MethodsTopical rThrombin was applied as a hemostatic aid during a surgical procedure (day 1). Adverse events and clinical laboratory abnormalities were recorded during the study. Immunogenicity samples were collected on days 1 and 29 (study end). Study results were summarized with descriptive statistics.ResultsThirty patients enrolled and 28 completed the study. Mean age was 6.9 years (range, 0.9-17.8 years); 40.0% of patients were girls. Flame and scald were the most common burn types (33.3% each, n = 10/30). Mean graft size was 3.6% total body surface area. Procedural pain (50.0% patients), pruritus (43.3%), and anemia (30.0%) were the most commonly reported adverse events. All adverse events and clinical laboratory abnormalities were considered unrelated to treatment. No patients developed anti-rThrombin product antibodies at day 29.ConclusionsIn pediatric patients undergoing burn wound excision and skin grafting, rThrombin was well tolerated and did not lead to the formation of anti-rThrombin product antibodies.Copyright © 2011. Published by Elsevier Inc.

47 keywords...

hide…